Tumor Biology

, Volume 36, Issue 4, pp 2869–2873 | Cite as

Cyr61 promotes growth of glioblastoma in vitro and in vivo

  • Gang Cheng
  • Hangyu Zhang
  • Leiming Zhang
  • Jianning Zhang
Research Article


The molecular regulation of the growth of glioblastoma (GBM) is not completely understood. Here, we show that the Cyr61 levels were significantly higher in GBM than in the adjacent non-tumor tissues. Overexpression of Cyr61 enhanced the viability of GBM cells, while inhibition of Cyr61 decreased the viability of GBM cells, in vitro and in vivo. Further analyses revealed that Cyr61 seemed to activate PI3K/Akt/mTor signaling pathway to increase cell growth in GBM cells. Taken together, our findings suggest a potential role of Cyr61 in GBM growth and highlight Cyr61 as a novel target for GBM therapy.


Glioblastoma (GBM) Cyr61 PI3K Akt mTor 



This work was financially supported by Capital Resident Health Training Program, No.: Z1311020400000.

Conflicts of interest



  1. 1.
    Chen J, Huang Q, Wang F. Inhibition of FoxO1 nuclear exclusion prevents metastasis of glioblastoma. Tumour Biol. 2014;35:7195–200.CrossRefPubMedGoogle Scholar
  2. 2.
    Li S, Gao Y, Ma W, Guo W, Zhou G, Cheng T, et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2. Tumour Biol. 2014;35:5593–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci. 2011;68:3149–63.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007;100:1337–45.CrossRefPubMedGoogle Scholar
  6. 6.
    Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. FEBS J. 2006;273:3639–49.CrossRefPubMedGoogle Scholar
  7. 7.
    Ye Q, Cai W, Zheng Y, Evers BM, She QB. ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer. Oncogene. 2014;33:1828–39.CrossRefPubMedGoogle Scholar
  8. 8.
    Terada N, Kulkarni P, Getzenberg RH. Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl. 2012;14:405–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 2003;10:141–52.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheng TY, Wu MS, Hua KT, Kuo ML, Lin MT. Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J Gastroenterol. 2014;20:1694–700.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shi W, Yin J, Chen Z, Chen H, Liu L, Meng Z. Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27. Tumour Biol 2014Google Scholar
  12. 12.
    Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C, et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res. 2004;64:1987–96.CrossRefPubMedGoogle Scholar
  13. 13.
    Goodwin CR, Lal B, Zhou X, Ho S, Xia S, Taeger A, et al. Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation. Cancer Res. 2010;70:2932–41.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst. 1973;51:1417–23.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Gang Cheng
    • 1
  • Hangyu Zhang
    • 2
  • Leiming Zhang
    • 1
  • Jianning Zhang
    • 1
  1. 1.Neurosurgery InstituteNavy General Hospital of PLABeijingChina
  2. 2.Neurosurgery InstituteChinese PLA General HospitalBeijingChina

Personalised recommendations